Biological role of anaplastic lymphoma kinase in neuroblastoma.

  title={Biological role of anaplastic lymphoma kinase in neuroblastoma.},
  author={Yuko Osajima-Hakomori and Izumi Miyake and Miki Ohira and Akira Nakagawara and Atsuko Nakagawa and Ryuichi Sakai},
  journal={The American journal of pathology},
  volume={167 1},

Figures and Tables from this paper

Anaplastic lymphoma kinase: signalling in development and disease

The role of ALK in development and disease is addressed, implications for the future are discussed and many chromosomal rearrangements leading to enhanced ALK activity are described.

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy

Normal ALK biology, the confirmed and putative roles of ALK in the development of human cancers and efforts to target ALK using small-molecule kinase inhibitors are summarized.

ALK is a Novel Dependence Receptor: Potential Implications in Development and Cancer

The biological significance of the ALK receptor in cancer and development is summarized, in perspective with its dependence receptor function, which could have important implications in the therapy of ALK-positive tumors harboring the chimeric or wild type ALK protein.

Anaplastic lymphoma kinase as a therapeutic target

Current understandings about the ALK tyrosine kinase and its implication in the oncogenesis of human cancers as a fusion protein or through mutations are described and its interest as a therapeutic target is discussed.

Advanced Neuroblastoma: Role of ALK Mutations

Neuroblastoma is an embryonal tumor derived from primitive cells of the sympathetic nervous system and is one of the most common solid tumors in childhood. Despite the significant advances, high-risk

Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors.

Targeting anaplastic lymphoma kinase in neuroblastoma

ALK in neuroblastoma is discussed, as well as the use of ALK TKIs and other strategies to inhibit tumor growth and current efforts combining novel approaches and increasing the understanding of the oncogenic role of AlK in Neuroblastoma are aimed at improving the efficacy ofALK TkIs as precision medicine options in the clinic.

The Role of Anaplastic Lymphoma Kinase in Human Cancers

The emerging role of possible therapeutic targets that could overcome the resistance to ALK inhibition in cancer are discussed, such as inhibition of other kinases involved in the pathway, inhibition of ALK mutant proteins through the development of new drugs based on its crystallography, and the use of antibodies against ALK.

Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy

A succinct summary of normal ALK biology, the confirmed and putative roles of ALK fusions and the full‐length ALK receptor in the development of human cancers, and efforts to target ALK using small‐molecule kinase inhibitors is provided.

Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer.

It is shown that the anaplastic lymphoma kinase (ALK) is aberrantly activated in ovarian cancer and ALK is identified as a potential therapeutic target in a subset of serous ovarian carcinoma and stromal sarcoma patients.



Expression of the ALK tyrosine kinase gene in neuroblastoma.

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

Molecular cloning of cDNAs for both the human and mouse ALK proteins reveal that ALK is a novel receptor protein-tyrosine kinase having a putative transmembrane domain and an extracellular domain and shows the greatest sequence similarity to LTK (leukocyte tyrosine Kinase) whose biological function is presently unknown.

Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.

Results indicate that reliable immunostaining of routine biopsy material for NPM-ALK and ALK proteins is feasible and of diagnostic importance, especially because t(2;5)+ ALCL cases have a good prognosis with appropriate treatment.

Translocations involving anaplastic lymphoma kinase (ALK)

This review will focus on the molecular function and signal transduction pathways activated by ALK fusion oncogenes, with recent advances and possible clinical implications to be discussed.

ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth

It is shown that mAb16-39 elicits tyrosine phosphorylation of endogenously expressed ALK in human neuroblastoma (SK-N-SH) cells, indicating an essential role of the mitogen-activated protein kinase (MAP kinase) signaling cascade in ALK-mediated growth and differentiation of neurons.

Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin*

It is proposed that the PTN-ALK axis can play a significant role during development and during disease processes because of the growth stimulatory effect of PTN on different cell lines in culture coincides with the endogenous expression of ALK mRNA.

Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types*

It is concluded that MK can act as a growth, survival, and angiogenic factor during tumorigenesis and signals through the ALK receptor.

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK), and unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

Anaplastic Lymphoma Kinase (ALK) was originally identified as a member of the insulin receptor subfamily of receptor tyrosine kinases that acquires transforming capability when truncated and fused to

Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3.

A unique phosphotyrosine-containing protein of MW 80,000, designated p80, was found only in AMS3 cells and not in other cell lines or mononuclear cells from healthy donors, and amino acid sequence analysis of its tryptic digests showed that p80 was a hitherto undescribed tyrosine phosphoprotein similar to Ltk (leukocyte tyrosinesine kinase).